Therapeutic antibodies against flagellated pseudomonas aeruginosa
AssigneeLostam Biopharmaceuticals Ltd
InventorLewis F. Neville
Life of this patent
Estimating the term…
Abstract
Improved antibodies are provided selected from human, dual-specific, chimeric or humanized antibodies, wherein said human chimeric and humanized antibodies specifically bind to flagellin type A or type B of P. aeruginosa, and said dual-specific antibodies specifically binds to flagella type A and type B of Pseudomonas aeruginosa, and said antibodies are protective against infection caused by P. aeruginosa. These antibodies as well as pharmaceutical composition comprising them are useful for the treatment of indications caused by P. aeruginosa infection.
Claims22
An antibody that specifically binds to flagella type A or type B of P. aeruginosa, but excluding a mouse monoclonal antibody.
3-5. (canceled)
11-30. (canceled)
A human IgG antibody that specifically binds to flagella type B, comprising the VH fragment fused to a human IgG1 heavy constant domain as set forth in SEQ ID NO:
- 15 and the VL fragment fused to a human IgG1 light constant domain as set forth in SEQ ID NO:
- 16.
32-33. (canceled)
40-44. (canceled)
A host cell, such as mouse myeloma NS0 and Chinese hamster ovary cells, or plant cells, such as tobacco, carrot and rice cells, which comprises at least one vector encoding for a human antibody that specifically binds to flagella type A or type B of P. aeruginosa.
(canceled)
48-56. (canceled)
Dependencies are inferred from the claim text.